UBS Group
VIRX

UBS Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

UBS Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-93,177
Closed -$15K – 11019
2024
Q4 		$15K Buy
93,177
+93,082
+97,981% +$18.3K ﹤0.01% 8059
2024
Q3 		$22 Sell
95
-1,595
-94% -$585 ﹤0.01% 9302
2024
Q2 		$920 Buy
1,690
+1,595
+1,679% +$1.26K ﹤0.01% 8733
2024
Q1 		$97 Sell
95
-168,573
-100% -$123K ﹤0.01% 8842
2023
Q4 		$96.1K Buy
168,668
+168,603
+259,389% +$103K ﹤0.01% 6194
2023
Q3 		$68 Buy
+65
New +$88 ﹤0.01% 8960
2023
Q1 		– Sell
-3,258
Closed -$4.76K – 10612
2022
Q4 		$4.76K Buy
3,258
+786
+32% +$2.3K ﹤0.01% 9280
2022
Q3 		$11K Buy
2,472
+2,463
+27,367% +$10.4K ﹤0.01% 8344
2022
Q2 		$0 Hold
9
– – ﹤0.01% 11106
2022
Q1 		$0 Hold
9
– – ﹤0.01% 11046
2021
Q4 		$0 Sell
9
-862
-99% -$4.6K ﹤0.01% 10843
2021
Q3 		$7K Buy
871
+862
+9,578% +$8.5K ﹤0.01% 8344
2021
Q2 		$0 Sell
9
-2
-18% -$20 ﹤0.01% 9927
2021
Q1 		$0 Sell
11
-1,191
-99% -$12.4K ﹤0.01% 9582
2020
Q4 		$9K Buy
+1,202
New +$6.27K ﹤0.01% 7583
2020
Q3 		– Sell
-4,152
Closed -$38K – 8497
2020
Q2 		$38K Buy
4,152
+2,345
+130% +$35.4K ﹤0.01% 6105
2020
Q1 		$27K Buy
1,807
+25
+1% +$543 ﹤0.01% 6304
2019
Q4 		$21K Buy
1,782
+928
+109% +$15.5K ﹤0.01% 6854
2019
Q3 		$22K Sell
854
-293
-26% -$8.46K ﹤0.01% 6688
2019
Q2 		$29K Buy
1,147
+271
+31% +$10.5K ﹤0.01% 6369
2019
Q1 		$38K Buy
876
+230
+36% +$5.21K ﹤0.01% 5758
2018
Q4 		$10K Sell
646
-202
-24% -$8.24K ﹤0.01% 7246
2018
Q3 		$60K Buy
848
+162
+24% +$12.3K ﹤0.01% 6031
2018
Q2 		$51K Buy
686
+131
+24% +$11.7K ﹤0.01% 5947
2018
Q1 		$52K Buy
555
+444
+400% +$76.1K ﹤0.01% 5690
2017
Q4 		$14K Sell
111
-136
-55% -$12.7K ﹤0.01% 6820
2017
Q3 		$17K Buy
247
+195
+375% +$15.9K ﹤0.01% 6575
2017
Q2 		$4K Buy
52
+26
+100% +$2.98K ﹤0.01% 7226
2017
Q1 		$4K Sell
26
-32
-55% -$4.58K ﹤0.01% 7097
2016
Q4 		$7K Buy
58
+33
+132% +$4.59K ﹤0.01% 7103
2016
Q3 		$4K Sell
25
-18
-42% -$2.54K ﹤0.01% 7220
2016
Q2 		$5K Buy
43
+31
+258% +$3.43K ﹤0.01% 7145
2016
Q1 		$1K Sell
12
-225
-95% -$34.1K ﹤0.01% 7470
2015
Q4 		$45K Buy
237
+157
+196% +$29.4K ﹤0.01% 5914
2015
Q3 		$14K Sell
80
-145
-64% -$52.3K ﹤0.01% 7031
2015
Q2 		$143K Sell
225
-1,329
-86% -$706K ﹤0.01% 5139
2015
Q1 		$799K Sell
1,554
-82
-5% -$41.4K ﹤0.01% 3763
2014
Q4 		$876K Buy
+1,636
New +$737K ﹤0.01% 3681

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

UBS Group's VIRX Position: Q1 2025 in Review

UBS Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 93,177 shares — an estimated $15K sold.

UBS Group first reported a position in VIRX in Q4 2014 and held it in 38 quarters. The position peaked at $876K in Q4 2014. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • UBS Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 93,177 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $15K.
  • UBS Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 38 quarters.
  • UBS Group's Viracta Therapeutics, Inc. Common Stock position peaked at $876K in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.